Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: an international randomised controlled trial.

Please use the buttons on the left to navigate our site and find out more about the PEXIVAS trial.

Christmas Closure 2014

Please note BCTU will be closed from 4pm on Tuesday 23rd December 2014 until 9am on Monday 5th January 2015.

Study Design

Multi-centre, international, open label, factorial design, randomised control trial in severe ANCA-associated vasculitis (AAV). Five hundred participants will be randomised, 1:1, to receive adjunctive plasma exchange (PLEX) in addition to standard immunosuppressive therapy and glucocorticoids (GC) or standard immunosuppressive therapy and GC without PLEX. The same 500 patients will be randomised, 1:1, to receive reduced-dose GC taper or standard-dose GC taper. 

We are very pleased to announce that the first patient was randomised into PEXIVAS on Tuesday 8th June 2010 from Addenbrooke's Hospital, Cambridge, UK.  


Trial Chief Investigator: David Jayne (UK and Europe), Peter A. Merkel (USA) and Michael Walsh (Canada)

Sponsor: Cambridge University Hospitals NHS Foundation Trust

Funding: National Institutes of Health Research (UK): Number, HTA 08/56/04, Food and Drug Administration/National Institutes of Health (USA): FDA R01 FD003516 and the National Institutes of Health (USA) - National Institute of Arthritis and Musculoskeletal and Skin Diseases: U54 AR0573319, National Health and Medical Research Council (Australia): 626939 and Canadian Institutes of Health Research (Canada): 211079.

EudraCT Number: 2009-013220-24

REC Outer West London: 09/H0709/56

MHRA: CTA Ref. 21857/0006/001-0001